Swastika Infra — RHP
Can Swastika Infra scale execution across its ₹916.55 crore uncompleted order book and reverse negative operating cash flows while remaining reliant on low-bid government utility contracts?
IPO Desk
Expert, evidence-led analysis of Draft Red Herring Prospectuses: how the business earns, where the offer money goes, what may be defensible, and which
Deliberately absent: No grey-market premium, subscription call, listing-day prediction, or buy/avoid verdict. The filing is the evidence; the decision remains yours.
NOPAPERFORMS SOLUTIONS — UDRHP
Can NoPaperForms sustain high growth and expand operating margins while diversifying beyond its core Meritto platform and mitigating top-vendor cloud infrastructure concentration?
SS RETAIL — RHP
Can SS Retail sustain its retail space efficiency and expand outside Maharashtra while managing high supplier concentration and working capital demands?
SONASELECTION INDIA — RHP
Can Sonaselection successfully sustain operating margins and transition working capital to positive cash flow as it shifts from job work to direct fabric manufacturing and garmenting?
Tempsens Instruments (India) — RHP
Can Tempsens sustain its margin expansion and export momentum while scaling capacity in specialized cables and electrical heating and optimizing its extended working capital cycle?
Kataria Dhulchand Pannalal Jewellers — DRHP
Can the company successfully diversify geographically beyond its flagship Ratlam store while turning around negative operating cash flows driven by heavy inventory requirements?
HERO MOTORS — RHP
Can Hero Motors successfully scale its high-margin EV and bike powertrain solutions globally while managing severe customer concentration and debt obligations?
PRASOL CHEMICALS — RHP
Can Prasol successfully ramp up Mahad facility capacity utilization and commercialize its 40-product developmental pipeline while navigating raw material import price volatility and historical operational disruptions?
PRANAV CONSTRUCTIONS — RHP
Can Pranav Constructions sustain its rapid revenue expansion and 26-month delivery turnaround while reversing negative operating cash flows and navigating geographic concentration in Mumbai's redevelopment market?
ARAGEN LIFE SCIENCES — DRHP
Can Aragen sustain its 18%+ revenue growth and margin expansion while scaling high-potent small molecules and biologics capabilities in a competitive global CRDMO landscape?
Sembcorp Green Infra — DRHP
Can Sembcorp Green Infra successfully scale its 4.04 GW/GWh under-construction pipeline and maintain high bid win rates while navigating public utility customer concentration and supplier disputes?